Abstracts

Biomarker Measure Strengthens Alcohol Use Association With HIV Viral Non-Suppression in PWH on ART

Background: Alcohol use among persons with HIV (PWH) predicts poor antiretroviral (ART) adherence and other co-morbidities, but its association with HIV viral non-suppression is inconsistent. This may be due to the limitations of alcohol self-report. The biomarker phosphatidylethanol, PEth, is an objective blood-based alcohol measure correlated with past month alcohol use. We assessed the association…

Global Transition to Dolutegravir-Based ART in Children and Adolescents 0-19 Years Living With HIV

Background: Dolutegravir (DTG)-based regimens are recommended as first-line antiretroviral therapy (ART) for all children and adolescents living with HIV (CALHIV). We describe transition to DTG in the multiregional IeDEA cohort. Methods: We included all CALHIV enrolled in IeDEA sites where DTG was available from 6 regions (Asia-Pacific, Latin America, Central Africa, West Africa, East Africa,…

Longitudinal Viral Outcomes in Kenyan Youth With HIV Switching to Dolutegravir-Based Therapy

Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is now recommended in all treatment lines in resource limited settings. Data on global implementation and longitudinal impact of DTG rollout for children and adolescents living with HIV (CAWH) are currently needed to inform care and policy. Methods: In a well characterized longitudinal cohort (since 2010) of perinatally infected…

HIV Viral Suppression Among Children and Adolescents 2 Years After Transition to Dolutegravir

Background: Children and adolescents with HIV experience high rates of treatment failure. Antiretroviral therapy (ART) containing dolutegravir has recently been rolled out across much of Africa and has several potential benefits over previously preferred ART regimens, though long-term real-world data in pediatric populations are lacking. Here, we report treatment outcomes among children and adolescents in…

Activated Proinflammatory NK Cells Promote Atherogenesis in Adolescents w/ Perinatally Acquired HIV 

Background: Perinatally acquired HIV (PHIV) and lifelong antiretroviral therapy (ART) may alter the development and function of the immune system. Published literature and our preliminary data suggest reprogramming of innate immune cells may accelerate aging and increase the risk for future end-organ complications, including cardiovascular disease (CVD). Natural killer (NK) cells are a heterogeneous group…

Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy

Background: Some antiretroviral agents, including tenofovir (TFV), may negatively impact bone health. Tenofovir alafenamide (TAF) results in lower TFV plasma levels than tenofovir disoproxil fumarate, and thus has a better bone safety profile. We examined the medium/long-term treatment effects of TAF-based antiretroviral therapies (ARTs) on bone safety in children and adolescents with HIV aged ≥2…

Birth Outcomes Following Bictegravir Use During Pregnancy

Background: Bictegravir (BIC), co-formulated in a tablet with tenofovir alafenamide and emtricitabine, is being increasingly prescribed to pregnant persons with HIV (PWH), yet limited birth outcome data have been reported. Methods: We conducted a descriptive analysis of PWH 18-45 years of age enrolled in at least one Pediatric HIV/AIDS Cohort Study (PHACS)-affiliated protocol who received…